drugset / Trial / NCT03613753
Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized phase II study compare survival outcomes and toxicity of two chemotherapy regimens (irinotecan plus lobaplatin or irinotecan) for the second-line treatment of recurrent small-cell lung cancer.
Timeline
- Start
- 2018-06-01
- Primary completion
- 2020-06-01
- Completion
- 2021-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Irinotecan | Small molecule | — | — |
| Subject | Lobaplatin | Small molecule | — | — |